Cochrane · systematic review · CD008593
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
Wulaningsih, W, Wardhana, A, Watkins, J, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
ColorectalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
IRI with fluoropyrimidines versus single agent IRI for advanced and/or metastatic colorectal cancer
Population: patients with advanced and/or metastatic colorectal cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (Death) IRI with fluoropyrimidines vs single agent IRI | HR 0.91 [0.81, 1.02] | 5 studies · 1728 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival (Disease progression) IRI with fluoropyrimidines vs single agent IRI | HR 0.68 [0.53, 0.83] | 3 studies · 600 participants | Moderate Downgraded: risk of bias |
Grade 3/4 diarrhea IRI with fluoropyrimidines vs single agent IRI | RR 0.66 [0.51, 0.85] | 5 studies · 1179 participants | Moderate Downgraded: risk of bias, imprecision |
Grade 3/4 nausea IRI with fluoropyrimidines vs single agent IRI | RR 0.33 [0.07, 1.58] | 3 studies · 209 participants | Low Downgraded: risk of bias, imprecision |